A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a Pediatric Brain Tumor Consortium report(†)

BACKGROUND: A phase I trial of veliparib (ABT-888), an oral poly(ADP-ribose) polymerase (PARP) inhibitor, and temozolomide (TMZ) was conducted in children with recurrent brain tumors to (i) estimate the maximum tolerated doses (MTDs) or recommended phase II doses (RP2Ds) of veliparib and TMZ; (ii) d...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Neuro Oncol
Auteurs principaux: Su, Jack M., Thompson, Patrick, Adesina, Adekunle, Li, Xiao-Nan, Kilburn, Lindsay, Onar-Thomas, Arzu, Kocak, Mehmet, Chyla, Brenda, McKeegan, Evelyn, Warren, Katherine E., Goldman, Stewart, Pollack, Ian F., Fouladi, Maryam, Chen, Alice, Giranda, Vincent, Boyett, James, Kun, Larry, Blaney, Susan M.
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2014
Sujets:
Pediatric Neuro-Oncology
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4232081/
https://ncbi.nlm.nih.gov/pubmed/24908656
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou103
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires